101 related articles for article (PubMed ID: 20836751)
21. Medical treatment options in patients with metastatic renal cell carcinoma.
Haferkamp A; Hohenfellner M
Nephrol Dial Transplant; 2007 Apr; 22(4):996-9. PubMed ID: 17210591
[No Abstract] [Full Text] [Related]
22. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
23. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
24. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.
Marshall FF
J Urol; 2005 Jun; 173(6):1919-20. PubMed ID: 15879776
[No Abstract] [Full Text] [Related]
25. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
26. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
27. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
Ramsey S; Aitchison M; Graham J; McMillan DC
BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
[TBL] [Abstract][Full Text] [Related]
28. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
29. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
30. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.
Takahashi Y; Childs RW
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6353S-9S. PubMed ID: 15448030
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
32. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
Brinkmann OA; Bruns F; Prott FJ; Hertle L
Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
Patard JJ
Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
[No Abstract] [Full Text] [Related]
34. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
35. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
[TBL] [Abstract][Full Text] [Related]
36. [Systemic treatment of renal-cell carcinoma--present status].
Steiner T; Schubert J
Dtsch Med Wochenschr; 2001 Sep; 126(39):1080-4. PubMed ID: 11602916
[No Abstract] [Full Text] [Related]
37. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
38. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
Vermaat JS; van der Tweel I; Mehra N; Sleijfer S; Haanen JB; Roodhart JM; Engwegen JY; Korse CM; Langenberg MH; Kruit W; Groenewegen G; Giles RH; Schellens JH; Beijnen JH; Voest EE
Ann Oncol; 2010 Jul; 21(7):1472-1481. PubMed ID: 20022911
[TBL] [Abstract][Full Text] [Related]
39. Combination immunotherapy in renal cell carcinoma.
Drake CG
Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
[No Abstract] [Full Text] [Related]
40. [Medical therapies for locally advanced/metastatic kidney cancer].
Afrit M; Yahyaoui Y; Bouzouita A; Hantous S; Labidi S; Chebil M; Ben Miled K; Escudier B; Boussen H
Presse Med; 2015 Feb; 44(2):135-43. PubMed ID: 25535168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]